Jubilant Life Sciences has introduced that its subsidiary, Jubilant Generics Ltd (Jubilant), has launched remdesivir for injection under the logo call ‘JUBI-R’ in the Indian market at a rate of Rs. 4,seven-hundred consistent with vial of a hundred mg (lyophilized injection). The Company will make the drug available to over 1,000 hospitals providing COVID-19 treatment in India via its distribution network.

Jubilant’s 24 hour help line will enhance get right of entry to to ‘JUBI-R’ at some stage in those pandemic instances, wherein timely get admission to to the drug can also show critical to remedy outcomes.
In order to increase accessibility of ‘JUBI-R’ to patients underneath the poverty line and to the front line paramedical workforce, Jubilant Bhartia Foundation, a no longer-for-earnings enterprise of Jubilant Group, is launching specific packages in India aimed toward distribution of the drug.

Lupin receives tentative USFDA nod for Empagliflozin drugs
Lupin receives tentative popularity of its Empagliflozin Tablets, 10 mg and 25 mg, from USFDA to market a customary model of Jardiance capsules, 10 mg and 25 mg, of Boehringer Ingelheim Pharma

The medicine used collectively with food plan and exercise to treat type 2 diabetes.